CoChat
Sign Up
Cited by 7

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Reduction of Allergic Lung Disease by Mucosal Application of Toxoplasma gondii-Derived Molecules: Possible Role of Carbohydrates

Korb, Elke, Drinić, Mirjana, Wagner, Angelika, Geissler, Nora, Inic-Kanada, Aleksandra, Peschke, Roman, Joachim, Anja, Wiedermann, Ursula, Schabussova, Irma·2021·Frontiers in Immunology
DOI 10.3389/fimmu.2020.612766PMC PMC7988086
Open this paper in CoChat — free account

Abstract

Background: The hygiene hypothesis suggests a link between parasitic infections and immune disorders, such as allergic diseases. We previously showed that infection with Toxoplasma gondii or systemic application of T. gondii tachyzoites lysate antigen (TLA) in a prophylactic, but not therapeutic protocol, prevented allergic airway inflammation in mice. Here we tested the effect of prophylactic and therapeutic application of TLA via the mucosal route. Methods: Mice were intranasally treated with TLA either i) prior to sensitization, ii) during sensitization and challenge, or iii) after sensitization with ovalbumin (OVA). Recruitment of inflammatory cells to the lung, cytokine levels in restimulated lung and spleen cell cultures as well as levels of OVA-specific antibodies in serum were measured. In parallel, the effect of native TLA, heat-inactivated (hiTLA) or deglycosylated TLA (dgTLA) on sensitized splenocytes was evaluated ex vivo. Results: When applied together with OVA i) during systemic sensitization and local challenge or ii) exclusively during local challenge, TLA reduced infiltration of eosinophils into the lung, OVA-specific type 2 cytokines in restimulated lung cell cultures, and partially, type 2 cytokines in restimulated spleen cell cultures in comparison to allergic controls. No beneficial effect was observed when TLA was applied prior to the start of sensitization. Analysis of epitope sugars on TLA indicated a high abundance of mannose, fucose, N-acetylglucosamine, and N-acetylgalactosamine. Deglycosylation of TLA, but not heat-inactivation, abolished the potential of TLA to reduce type 2 responses ex vivo, suggesting a significant role of carbohydrates in immunomodulation. Conclusion: We showed that mucosal application of TLA reduced the development of experimental allergy in mice. The beneficial effects depended on the timing of the application in relation to the time point of sensitization. Not only co-application, but also therapy in sensitized/allergic animals with native TLA reduced local allergic responses. Furthermore, we show that TLA is highly glycosylated and glycoconjugates seem to play a role in anti-allergic effects. In summary, given the powerful modulatory effect that TLA exhibits, understanding its exact mechanisms of action may lead to the development of novel immunomodulators in clinical application.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2020.612766

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Prophylactic treatment with TLA fails to prevent allergic airway inflammation. (A) Experimental design. (B) Differential cell counts in bronchoalveolar lavage (BALF). (C) Levels of OVA-specific antibody IgG2a in BALF collected at the end of the experiment. (D) Average histopathology score and number of Periodic acid-Schiff (PAS)-positive goblet cells of lung sections. (E) PAS or hematoxylin and eosin (H&E)-stained lung sections from 1 representative example from each group (n = 5); scale bars, 100 µm. (F) Levels of IL-4, IL-5, IL-10, IL-13, and IFN-γ after medium and ovalbumin (OVA) restimulation of lung cells. (G) Levels of IL-4, IL-5, IL-10, and IFN-γ after medium and OVA restimulation of spleen cells. (H) Levels of OVA-specific antibody IgG2a in serum collected at the beginning and at the end of the experiment. (I) Release of β-hexosaminidase by rat basophil leukemia (RBL) cells. Graphs show results from 1 representative experiment from 2 independent experiments with 5 mice per group ( Figures 1B–I ). Error bars show mean ± SEM. TLA, tachyzoites lysate antigen; OVA, ovalbumin; i.n., intranasal; i.p., intraperitoneal; macro, macrophages; eos, eosinophils; neutro, neutrophils; lympho, lymphocytes; OD, optical density; nd, not detectable; ns, not significant; ***P < 0.001.
Figure 1 Prophylactic treatment with TLA fails to prevent allergic airway inflammation. (A) Experimental design. (B) Differential cell counts in bronchoalveolar lavage (BALF). (C) Levels of OVA-specific antibody IgG2a in BALF collected at the end of the experiment. (D) Average histopathology score and number of Periodic acid-Schiff (PAS)-positive goblet cells of lung sections. (E) PAS or hematoxylin and eosin (H&E)-stained lung sections from 1 representative example from each group (n = 5); scale bars, 100 µm. (F) Levels of IL-4, IL-5, IL-10, IL-13, and IFN-γ after medium and ovalbumin (OVA) restimulation of lung cells. (G) Levels of IL-4, IL-5, IL-10, and IFN-γ after medium and OVA restimulation of spleen cells. (H) Levels of OVA-specific antibody IgG2a in serum collected at the beginning and at the end of the experiment. (I) Release of β-hexosaminidase by rat basophil leukemia (RBL) cells. Graphs show results from 1 representative experiment from 2 independent experiments with 5 mice per group ( Figures 1B–I ). Error bars show mean ± SEM. TLA, tachyzoites lysate antigen; OVA, ovalbumin; i.n., intranasal; i.p., intraperitoneal; macro, macrophages; eos, eosinophils; neutro, neutrophils; lympho, lymphocytes; OD, optical density; nd, not detectable; ns, not significant; ***P < 0.001.CC BY · PubMed Central
Figure 2 TLA reduces allergic airway inflammation in a co-application model. (A), Experimental design. (B) Airway hyperresponsiveness in response to methacholine. (C) Differential cell count in bronchoalveolar lavage (BALF). (D) Levels of OVA-specific antibody IgG2a in BALF collected at the end of the experiment. (E) Average histopathology score and number of Periodic acid-Schiff (PAS)-positive goblet cells of lung sections. (F) PAS or hematoxylin and eosin (H&E)-stained lung sections from 1 representative example from each group (n = 5); scale bars, 100 µm. (G) Levels of IL-4, IL-5, IL-10, IL-13, and IFN-γ after medium and OVA restimulation of lung cells. Graphs show results from 1 experiment with 5 mice per group ( Figure 2B , PBS/PBS group in Figures 2C–G ) or from 1 representative experiment from 2 independent experiments with 5 mice per group (groups PBS/OVA and TLA/OVA, Figures 2C–G ). Error bars show mean ± SEM. TLA, tachyzoites lysate antigen; OVA, ovalbumin; i.n., intranasal; i.p., intraperitoneal; macro, macrophages; eos, eosinophils; neutro, neutrophils; lympho, lymphocytes; nd, not detectable; ns, not significant; OD, optical density; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 2 TLA reduces allergic airway inflammation in a co-application model. (A), Experimental design. (B) Airway hyperresponsiveness in response to methacholine. (C) Differential cell count in bronchoalveolar lavage (BALF). (D) Levels of OVA-specific antibody IgG2a in BALF collected at the end of the experiment. (E) Average histopathology score and number of Periodic acid-Schiff (PAS)-positive goblet cells of lung sections. (F) PAS or hematoxylin and eosin (H&E)-stained lung sections from 1 representative example from each group (n = 5); scale bars, 100 µm. (G) Levels of IL-4, IL-5, IL-10, IL-13, and IFN-γ after medium and OVA restimulation of lung cells. Graphs show results from 1 experiment with 5 mice per group ( Figure 2B , PBS/PBS group in Figures 2C–G ) or from 1 representative experiment from 2 independent experiments with 5 mice per group (groups PBS/OVA and TLA/OVA, Figures 2C–G ). Error bars show mean ± SEM. TLA, tachyzoites lysate antigen; OVA, ovalbumin; i.n., intranasal; i.p., intraperitoneal; macro, macrophages; eos, eosinophils; neutro, neutrophils; lympho, lymphocytes; nd, not detectable; ns, not significant; OD, optical density; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure 3 TLA reduces systemic IL-4 and serum IgE-levels in a co-application model. (A) Levels of IL-4, IL-5, IL-10, and IFN-γ after medium and ovalbumin (OVA) restimulation of spleen cells from mice treated as in Figure 2A . (B) Levels of OVA-specific antibodies IgG1 and IgG2a in serum collected at the beginning and at the end of the experiment. (C) Release of β-hexosaminidase by rat basophil leukemia (RBL) cells. Graphs show results from 1 experiment with 5 mice per group (PBS/PBS) or 1 representative experiment from 2 independent experiments with 5 mice per group (PBS/OVA and TLA/OVA). Error bars show mean ± SEM. TLA, tachyzoites lysate antigen; OD, optical density; nd, not detectable; ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 3 TLA reduces systemic IL-4 and serum IgE-levels in a co-application model. (A) Levels of IL-4, IL-5, IL-10, and IFN-γ after medium and ovalbumin (OVA) restimulation of spleen cells from mice treated as in Figure 2A . (B) Levels of OVA-specific antibodies IgG1 and IgG2a in serum collected at the beginning and at the end of the experiment. (C) Release of β-hexosaminidase by rat basophil leukemia (RBL) cells. Graphs show results from 1 experiment with 5 mice per group (PBS/PBS) or 1 representative experiment from 2 independent experiments with 5 mice per group (PBS/OVA and TLA/OVA). Error bars show mean ± SEM. TLA, tachyzoites lysate antigen; OD, optical density; nd, not detectable; ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure 4 Therapeutic treatment with native or heat-inactivated TLA reduces allergic airway inflammation. (A) Experimental design. (B) Differential cell count in bronchoalveolar lavage (BALF). (C) Levels of OVA-specific antibody IgG2a in BALF collected at the end of the experiment. (D) Average histopathology score and number of Periodic acid-Schiff (PAS)-positive goblet cells of lung sections. (E) PAS or H&E-stained lung sections from 1 representative example from each group (n = 5); scale bars, 100 µm. (F) Levels of IL-4, IL-5, IL-10, IL-13, and IFN-γ after medium and OVA restimulation of lung cells. Graphs show results from 1 representative experiment from 2 independent experiments with 5 mice per group. Error bars show mean ± SEM. TLA, tachyzoites lysate antigen; hiTLA, heat-inactivated; OVA, ovalbumin; i.n., intranasal; i.p., intraperitoneal; macro, macrophages; eos, eosinophils; neutro, neutrophils; lympho, lymphocytes; n.s., not significant; OD, optical density; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 4 Therapeutic treatment with native or heat-inactivated TLA reduces allergic airway inflammation. (A) Experimental design. (B) Differential cell count in bronchoalveolar lavage (BALF). (C) Levels of OVA-specific antibody IgG2a in BALF collected at the end of the experiment. (D) Average histopathology score and number of Periodic acid-Schiff (PAS)-positive goblet cells of lung sections. (E) PAS or H&E-stained lung sections from 1 representative example from each group (n = 5); scale bars, 100 µm. (F) Levels of IL-4, IL-5, IL-10, IL-13, and IFN-γ after medium and OVA restimulation of lung cells. Graphs show results from 1 representative experiment from 2 independent experiments with 5 mice per group. Error bars show mean ± SEM. TLA, tachyzoites lysate antigen; hiTLA, heat-inactivated; OVA, ovalbumin; i.n., intranasal; i.p., intraperitoneal; macro, macrophages; eos, eosinophils; neutro, neutrophils; lympho, lymphocytes; n.s., not significant; OD, optical density; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure 5 Therapeutic treatment with native or heat-inactivated TLA reduces systemic type 2 responses. (A) Levels of IL-4, IL-5, IL-10, and IFN-γ after medium and ovalbumin (OVA) restimulation of spleen cells from mice treated as in Figure 4A . (B) Levels of OVA-specific antibodies IgG1 and IgG2a in serum collected at the beginning and at the end of the experiment. (C) Release of β-hexosaminidase by rat basophil leukemia (RBL) cells. Graphs show results from 1 representative experiment from 2 independent experiments with 5 mice per group. Error bars show mean ± SEM. nd, not detectable; TLA, tachyzoites lysate antigen; hiTLA, heat-inactivated TLA; ns, not significant; OD, optical density; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 5 Therapeutic treatment with native or heat-inactivated TLA reduces systemic type 2 responses. (A) Levels of IL-4, IL-5, IL-10, and IFN-γ after medium and ovalbumin (OVA) restimulation of spleen cells from mice treated as in Figure 4A . (B) Levels of OVA-specific antibodies IgG1 and IgG2a in serum collected at the beginning and at the end of the experiment. (C) Release of β-hexosaminidase by rat basophil leukemia (RBL) cells. Graphs show results from 1 representative experiment from 2 independent experiments with 5 mice per group. Error bars show mean ± SEM. nd, not detectable; TLA, tachyzoites lysate antigen; hiTLA, heat-inactivated TLA; ns, not significant; OD, optical density; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central
Figure 6 Characterization of TLA with enzyme-linked lectin assay (ELLA) and lectin-Western blots reveal a complex pattern of epitope sugars: (A) abundance of tachyzoite lysate antigen’s (TLA)s epitope sugars evaluated with ELLA. (B) Distribution of epitope sugars on proteins and peptides of TLA. AAA Anguilla anguilla agglutinin; UEA-I Ulex europaeus agglutinin-I; RCA-II Ricinus communis agglutinin II; BPA Bauhinia purpurea agglutinin; PHA-L phytohemagglutinin; WFA Wisteria floribunda agglutinin; HPA Helix pomatia agglutinin; DBA Dolichos biflorus agglutinin; GS-II Griffonia simplicifolia agglutinin; WGA Wheat germ agglutinin; LEL Lycopersicon esculentum lectin; SNA Sambucus nigra agglutinin; GS1B4 Griffonia simplifolica-1B4; PNA peanut agglutinin; GNA Galanthus nivalis agglutinin; ConA Concanavalin A; MAA Maackia amurensis agglutinin. TLA, tachyzoites lysate antigen; OD, optical density.
Figure 6 Characterization of TLA with enzyme-linked lectin assay (ELLA) and lectin-Western blots reveal a complex pattern of epitope sugars: (A) abundance of tachyzoite lysate antigen’s (TLA)s epitope sugars evaluated with ELLA. (B) Distribution of epitope sugars on proteins and peptides of TLA. AAA Anguilla anguilla agglutinin; UEA-I Ulex europaeus agglutinin-I; RCA-II Ricinus communis agglutinin II; BPA Bauhinia purpurea agglutinin; PHA-L phytohemagglutinin; WFA Wisteria floribunda agglutinin; HPA Helix pomatia agglutinin; DBA Dolichos biflorus agglutinin; GS-II Griffonia simplicifolia agglutinin; WGA Wheat germ agglutinin; LEL Lycopersicon esculentum lectin; SNA Sambucus nigra agglutinin; GS1B4 Griffonia simplifolica-1B4; PNA peanut agglutinin; GNA Galanthus nivalis agglutinin; ConA Concanavalin A; MAA Maackia amurensis agglutinin. TLA, tachyzoites lysate antigen; OD, optical density.CC BY · PubMed Central
Figure 7 Ex vivo stimulation with TLA and hiTLA, but not dgTLA reduces type 2 cytokines and elevates IFN-γ. Levels of IL-4, IL-5, IL-10, and IFN-γ after stimulation with medium, TLA, hiTLA or dgTLA, followed by stimulation with medium or ovalbumin (OVA) of splenocytes excised from allergic control mice after sensitization and challenge. Graphs show results from 1 representative experiment from 2 independent experiments with 3 mice per group. Error bars show mean ± SEM. nd not detectable; TLA, tachyzoites lysate antigen; hiTLA, heat-inactivated TLA; dgTLA, deglycosylated TLA; inc, incubation. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Figure 7 Ex vivo stimulation with TLA and hiTLA, but not dgTLA reduces type 2 cytokines and elevates IFN-γ. Levels of IL-4, IL-5, IL-10, and IFN-γ after stimulation with medium, TLA, hiTLA or dgTLA, followed by stimulation with medium or ovalbumin (OVA) of splenocytes excised from allergic control mice after sensitization and challenge. Graphs show results from 1 representative experiment from 2 independent experiments with 3 mice per group. Error bars show mean ± SEM. nd not detectable; TLA, tachyzoites lysate antigen; hiTLA, heat-inactivated TLA; dgTLA, deglycosylated TLA; inc, incubation. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 70

  1. Schatz, 2014, The allergic asthma phenotype, J Allergy Clin Immunol In Pract, 2, 645, 10.1016/j.jaip.2014.09.004 · DOI
  2. Bateman, 2008, Global strategy for asthma management and prevention: GINA executive summary, Eur Respir J, 31, 10.1183/09031936.00138707 · DOI · Paper page
  3. D’Amato, 2014, Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review, Multidiscip Respir Med, 9, 23, 10.1186/2049-6958-9-23 · DOI
  4. Okano, 2009, Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis, Clin Exp Immunol, 158, 10.1111/j.1365-2249.2009.04010.x · DOI
  5. Donohue, 2004, Therapeutic responses in asthma and COPD, Bronchodilators Chest, 126, 125S, 10.1378/chest.126.2_suppl_1.125S · DOI
  6. Yukselen, 2014, Role of immunotherapy in the treatment of allergic asthma, World J Clin Cases, 2, 10.12998/wjcc.v2.i12.859 · DOI
  7. Abramson, 2010, Injection allergen immunotherapy for asthma, Cochrane Database Syst Rev, CD001186, 10.1002/14651858.CD001186.pub2 · DOI
  8. Hedlin, 2012, The role of immunotherapy in the management of childhood asthma, Ther Adv Respir Dis, 6, 10.1177/1753465812439793 · DOI
  9. Calamita, 2006, Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method, Allergy, 61, 10.1111/j.1398-9995.2006.01205.x · DOI
  10. Zhernov, 2019, Recombinant allergens for immunotherapy: state of the art, Curr Opin Allergy Clin Immunol, 19, 10.1097/ACI.0000000000000536 · DOI
  11. Fujita, 2012, Mechanisms of allergen-specific immunotherapy, Clin Trans Allergy, 2, 2, 10.1186/2045-7022-2-2 · DOI
  12. Hill, 2005, Biology and epidemiology of Toxoplasma gondii in man and animals, Anim Health Res Rev, 6, 41, 10.1079/AHR2005100 · DOI
  13. Montoya, 2004, Toxoplasmosis, Lancet, 363, 10.1016/S0140-6736(04)16412-X · DOI
  14. Hill, 2002, Toxoplasma gondii: transmission, diagnosis and prevention, Clin Microbiol Infect, 8, 10.1046/j.1469-0691.2002.00485.x · DOI
  15. Blader, 2015, Lytic Cycle of Toxoplasma gondii: 15 Years Later, Annu Rev Microbiol, 69, 10.1146/annurev-micro-091014-104100 · DOI
  16. Strachan, 1989, Hay fever, hygiene, and household size, BMJ, 299, 10.1136/bmj.299.6710.1259 · DOI · Paper page
  17. Bach, 2002, The effect of infections on susceptibility to autoimmune and allergic diseases, N Engl J Med, 347, 10.1056/NEJMra020100 · DOI
  18. Droste, 2000, Does the use of antibiotics in early childhood increase the risk of asthma and allergic disease, Clin Exp Allergy, 30, 10.1046/j.1365-2222.2000.00939.x · DOI
  19. von Mutius, 2016, The microbial environment and its influence on asthma prevention in early life, J Allergy Clin Immunol, 137, 10.1016/j.jaci.2015.12.1301 · DOI · Paper page
  20. Yazdanbakhsh, 2004, Parasites and the hygiene hypothesis: regulating the immune system, Clin Rev Allergy Immunol, 26, 15, 10.1385/CRIAI:26:1:15 · DOI
  21. Fenoy, 2015, Toxoplasma gondii infection modulate systemic allergic immune response in BALB/c mice, Exp Parasitol, 154, 47, 10.1016/j.exppara.2015.04.001 · DOI · Paper page
  22. Wagner, 2009, Immunoregulation by Toxoplasma gondii infection prevents allergic immune responses in mice, Int J Parasitol, 39, 10.1016/j.ijpara.2008.09.003 · DOI
  23. Wagner, 2016, Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy, PloS One, 11, e0155081, 10.1371/journal.pone.0155081 · DOI
  24. Drinic, 2017, Toxoplasma gondii tachyzoite-extract acts as a potent immunomodulator against allergic sensitization and airway inflammation, Sci Rep, 7, 15211, 10.1038/s41598-017-15663-4 · DOI
  25. Hughes, 1986, In vitro culture of Toxoplasma gondii in primary and established cell lines, Int J Parasitol, 16, 10.1016/0020-7519(86)90109-8 · DOI
  26. da Costa-Silva, 2012, Toxoplasma gondii antigens: recovery analysis of tachyzoites cultivated in Vero cell maintained in serum free medium, Exp Parasitol, 130, 10.1016/j.exppara.2012.01.005 · DOI
  27. Smole, 2017, Murine models for mucosal tolerance in allergy, Semin Immunol, 30, 12, 10.1016/j.smim.2017.07.007 · DOI
  28. Goetz, 2014, Regulatory Aspects and Approval of Biopharmaceuticals for Mucosal Delivery: Quality, Toxicology, and Clinical Aspects, Mucosal Deliv Biopharm: Biol Challenges Strateg, 10.1007/978-1-4614-9524-6_25 · DOI
  29. Zwicker, 2018, Prophylactic and therapeutic inhibition of allergic airway inflammation by probiotic Escherichia coli O83, J Allergy Clin Immunol, 142, 1987, 10.1016/j.jaci.2018.07.029 · DOI
  30. Sarate, 2019, E. coli Nissle 1917 is a safe mucosal delivery vector for a birch-grass pollen chimera to prevent allergic poly-sensitization, Mucosal Immunol, 12, 10.1038/s41385-018-0084-6 · DOI
  31. Schabussova, 2011, Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization, Vaccine, 29, 10.1016/j.vaccine.2010.12.101 · DOI
  32. Fauquenoy, 2008, Proteomics and glycomics analyses of N-glycosylated structures involved in Toxoplasma gondii–host cell interactions, Mol Cell Proteomics, 7, 891, 10.1074/mcp.M700391-MCP200 · DOI
  33. Possenti, 2013, Global proteomic analysis of the oocyst/sporozoite of Toxoplasma gondii reveals commitment to a host-independent lifestyle, BMC Genomics, 14, 183, 10.1186/1471-2164-14-183 · DOI
  34. Arroyo-Olarte, 2015, Phosphatidylthreonine and Lipid-Mediated Control of Parasite Virulence, PloS Biol, 13, e1002288, 10.1371/journal.pbio.1002288 · DOI
  35. Besteiro, 2008, Lipidomic analysis of Toxoplasma gondii tachyzoites rhoptries: further insights into the role of cholesterol, Biochem J, 415, 87, 10.1042/BJ20080795 · DOI
  36. Bergeron, 1997, Biochemical analysis of a bladder-cancer-associated mucin: structural features and epitope characterization, Biochem J, 321, 10.1042/bj3210889 · DOI
  37. Thompson, 2011, Optimization of the enzyme-linked lectin assay for enhanced glycoprotein and glycoconjugate analysis, Anal Biochem, 413, 10.1016/j.ab.2011.02.013 · DOI
  38. Chong, 1998, Measurement of bronchoconstriction using whole-body plethysmograph: comparison of freely moving versus restrained guinea pigs, J Pharmacol Toxicol Methods, 39, 10.1016/S1056-8719(98)00021-5 · DOI
  39. Lajoie, 2014, IL-21 receptor signalling partially mediates Th2-mediated allergic airway responses, Clin Exp Allergy, 44, 10.1111/cea.12341 · DOI
  40. Zaiss, 2015, The Intestinal Microbiota Contributes to the Ability of Helminths to Modulate Allergic Inflammation, Immunity, 43, 998, 10.1016/j.immuni.2015.09.012 · DOI · Paper page
  41. Skevaki, 2018, Influenza-derived peptides cross-react with allergens and provide asthma protection, J Allergy Clin Immunol, 142, 10.1016/j.jaci.2017.07.056 · DOI
  42. Repa, 2003, Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy, Vaccine, 22, 87, 10.1016/S0264-410X(03)00528-0 · DOI
  43. Matricardi, 2000, Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study, BMJ, 320, 10.1136/bmj.320.7232.412 · DOI
  44. Homayun, 2019, Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals, Pharmaceutics, 11, 129, 10.3390/pharmaceutics11030129 · DOI · Paper page
  45. Russell, 2015, Mucosal Vaccines: An Overview. Mucosal immunology
  46. Holmgren, 2005, Mucosal immunity and vaccines, Nat Med, 11, 10.1038/nm1213 · DOI
  47. Carter, 2011, Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults, Drugs, 71, 10.2165/11206860-000000000-00000 · DOI
  48. Fenoy, 2009, Toxoplasma gondii infection blocks the development of allergic airway inflammation in BALB/c mice, Clin Exp Immunol, 155, 10.1111/j.1365-2249.2008.03813.x · DOI
  49. Valenta, 2019, Early prevention instead of mending late damage in allergy, EBioMedicine, 45, 10.1016/j.ebiom.2019.06.042 · DOI
  50. Demoly, 2015, “The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis”, Clin Trans Allergy, 5, 18, 10.1186/s13601-015-0061-z · DOI
  51. Coyle, 1996, Mice lacking the IFN-gamma receptor have impaired ability to resolve a lung eosinophilic inflammatory response associated with a prolonged capacity of T cells to exhibit a Th2 cytokine profile, J Immunol, 156, 10.4049/jimmunol.156.8.2680 · DOI
  52. Suzuki, 1988, Interferon-gamma: the major mediator of resistance against Toxoplasma gondii, Science, 240, 10.1126/science.3128869 · DOI
  53. Sturge, 2014, Complex immune cell interplay in the gamma interferon response during Toxoplasma gondii infection, Infect Immun, 82, 10.1128/IAI.01722-14 · DOI
  54. Schabussova, 2012, Perinatal maternal administration of Lactobacillus paracasei NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy, PloS One, 7, e40271, 10.1371/journal.pone.0040271 · DOI
  55. Cantani, 2005, Significant decrease of IgE antibodies after a three-year controlled study of specific immunotherapy to pollen allergens in children with allergic asthma, Eur Rev Med Pharmacol Sci, 9
  56. Akdis, 2011, Mechanisms of allergen-specific immunotherapy, J Allergy Clin Immunol, 127, 18, 10.1016/j.jaci.2010.11.030 · DOI
  57. Wilson, 2019, Sweet and CRISP(R)y parasite engineering, J Biol Chem, 294, 10.1074/jbc.H118.007210 · DOI
  58. Gas-Pascual, 2019, CRISPR/Cas9 and glycomics tools for Toxoplasma glycobiology, J Biol Chem, 294, 10.1074/jbc.RA118.006072 · DOI
  59. Greenwell, 2008, Purification and analysis of DNases of Tritrichomonas foetus: evidence that these enzymes are glycoproteins, Int J Parasitol, 38, 10.1016/j.ijpara.2007.10.012 · DOI
  60. Piazza, 1996, Reactivity of Trypanosoma cruzi strains with peanut agglutinin (PNA) correlates with number of in vitro infected host cells, Acta Trop, 61, 41, 10.1016/0001-706X(95)00139-6 · DOI
  61. Kantelhardt, 2002, Fuc(alpha1–>3)GalNAc-: the major antigenic motif of Schistosoma mansoni glycolipids implicated in infection sera and keyhole-limpet haemocyanin cross-reactivity, Biochem J, 366, 10.1042/bj20011678 · DOI
  62. Levery, 1992, Characterization of a series of novel fucose-containing glycosphingolipid immunogens from eggs of Schistosoma mansoni, J Biol Chem, 267, 10.1016/S0021-9258(18)42800-1 · DOI
  63. Moran, 2008, Relevance of fucosylation and Lewis antigen expression in the bacterial gastroduodenal pathogen Helicobacter pylori, Carbohydr Res, 343, 10.1016/j.carres.2007.12.012 · DOI
  64. Garami, 2001, Glycosylation defects and virulence phenotypes of Leishmania mexicana phosphomannomutase and dolicholphosphate-mannose synthase gene deletion mutants, Mol Cell Biol, 21, 10.1128/MCB.21.23.8168-8183.2001 · DOI
  65. van den Berg, 2012, An evolutionary perspective on C-type lectins in infection and immunity, Ann N Y Acad Sci, 1253, 10.1111/j.1749-6632.2011.06392.x · DOI
  66. Mascanfroni, 2011, Endogenous lectins shape the function of dendritic cells and tailor adaptive immunity: mechanisms and biomedical applications, Int Immunopharmacol, 11, 10.1016/j.intimp.2011.01.021 · DOI
  67. Coppens, 2020, Chapter 8 - Biochemistry and metabolism of Toxoplasma gondii: lipid synthesis and uptake, 10.1016/B978-0-12-815041-2.00008-6 · DOI
  68. Debierre-Grockiego, 2007, Fatty acids isolated from Toxoplasma gondii reduce glycosylphosphatidylinositol-induced tumor necrosis factor alpha production through inhibition of the NF-kappaB signaling pathway, Infect Immun, 75, 10.1128/IAI.01431-06 · DOI
  69. McSorley, 2012, Helminth infections and host immune regulation, Clin Microbiol Rev, 25, 585, 10.1128/CMR.05040-11 · DOI · Paper page
  70. Schabussova, 2013, Oesophagostomum dentatum extract modulates T cell-dependent immune responses to bystander antigens and prevents the development of allergy in mice, PloS One, 8, e67544, 10.1371/journal.pone.0067544 · DOI

Cited by

Sorted by citations

Metadata

Authors
Korb, E., Drinić, M., Wagner, A., Geissler, N., Inic-Kanada, A., Peschke, R., Joachim, A., Wiedermann, U., & Schabussova, I.
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2021-03-10
Volume
11
ISSN
1664-3224
DOI
10.3389/fimmu.2020.612766
PMC
PMC7988086
Cited by
7
References
1
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Austrian Science Fund (SFB 4612)
  • OeAD-GmbH (CZ 17/2019, CZ 16/2019, SRB 20/2018, PL 04/2019)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review